Sarepta Therapeutics, Inc.

Sarepta Therapeutics Misses on Revenue, Stock Down 4.89%

Sarepta Therapeutics reported a wider-than-expected loss per share, which surprised analysts positively, but the lack of revenue data and guidance contributed to a stock decline of nearly 5%. Investors may be concerned about the company's future performance without clear revenue expectations. The stock reaction reflects uncertainty in the market regarding the company's growth trajectory and pipeline developments.